Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  2012-01-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00259-011-2031-6PMID 22223169
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT

  2011cited by this paper
• Role of [18F]FDG-PET/CT in the detection of occult recurrent medullary thyroid cancer

  2010cited by this paper
• Clinical Value of 18-Fluorine-Fluorodihydroxyphenylalanine Positron Emission Tomography/Computed Tomography in the Follow-Up of Medullary Thyroid Carcinoma

  2010cited by this paper
• Medullary thyroid carcinoma.

  2010cited by this paper
• Ga-68 DOTATOC PET, Endoscopic Ultrasonography, and Multidetector CT in the Diagnosis of Duodenopancreatic Neuroendocrine Tumors: A Single-Centre Retrospective Study

  2010cited by this paper
• Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.

  2010cited by this paper
• The Prognostic Value of 2-Deoxy-2-[18F]Fluoro-d-Glucose Positron Emission Tomography in Patients With Suspected Residual or Recurrent Medullary Thyroid Carcinoma

  2010cited by this paper
• Imaging of neuroendocrine tumours.

  2010cited by this paper
• Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association

  2009cited by this paper
• 68Ga-somatostatin analogues PET and 18F-DOPA PET in medullary thyroid carcinoma

  2009cited by this paper
• The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT

  2009cited by this paper
• Comparison of 68Ga-DOTATATE and 18F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma

  2009cited by this paper
• New therapeutic approaches to treat medullary thyroid carcinoma

  2008cited by this paper
• Role of PET in medullary thyroid carcinoma.

  2008cited by this paper
• The role of 18F-FDG PET/CT in detecting metastatic deposits of recurrent medullary thyroid carcinoma: a prospective study.

  2008cited by this paper
• 18F-Dihydroxyphenylalanine PET in Patients with Biochemical Evidence of Medullary Thyroid Cancer: Relation to Tumor Differentiation

  2008cited by this paper
• Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer.

  2008cited by this paper
• Detection of Occult Medullary Thyroid Cancer Recurrence with 2-Deoxy-2-[F-18]fluoro-d-glucose-PET and PET/CT

  2007cited by this paper
• Sensitivity and prognostic value of positron emission tomography with F-18-fluorodeoxyglucose and sensitivity of immunoscintigraphy in patients with medullary thyroid carcinoma treated with anticarcinoembryonic antigen-targeted radioimmunotherapy.

  2007cited by this paper
• Diagnostic Accuracy of 18F-FDG PET in Restaging Patients with Medullary Thyroid Carcinoma and Elevated Calcitonin Levels

  2007cited by this paper
• Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma

  2007cited by this paper
• Imaging medullary thyroid carcinoma with persistent elevated calcitonin levels.

  2007cited by this paper
• Imaging of neuroendocrine tumors.

  2006cited by this paper
• Review of fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in the follow-up of medullary and anaplastic thyroid carcinomas.

  2005cited by this paper
• Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas

  2004cited by this paper
• Impact of 18F-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography (FDG-PET) in Patients with Biochemical Evidence of Recurrent or Residual Medullary Thyroid Cancer

  2004cited by this paper
• 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: a clinical study and an analysis of the literature

  2004cited by this paper
• FDG-PET: procedure guidelines for tumour imaging

  2003cited by this paper
• Long-term outcome of medullary thyroid carcinoma in patients with normal postoperative medical imaging

  2003cited by this paper
• 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma.

  2002cited by this paper
• Immunohistochemical detection of somatostatin receptor types 1–5 in medullary carcinoma of the thyroid

  2001cited by this paper
• 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels

  2001cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: results of a multicentre study

  2001cited by this paper
• The value of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with medullary thyroid cancer

  2000cited by this paper
• Medullary thyroid carcinoma

  2000cited by this paper
• The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer.

  2000cited by this paper
• Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study

  1999cited by this paper
• Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen.

  1998cited by this paper
• Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?

  1997cited by this paper
• Anti‐carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma

  1997cited by this paper
• Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.

  1996cited by this paper
• The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid.

  1994cited by this paper
• Somatostatin receptors and somatostatin content in medullary thyroid carcinomas.

  1991cited by this paper
• Relation of Doubling Time of Plasma Calcitonin Levels to Prognosis and Recurrence of Medullary Thyroid Carcinoma

  1984cited by this paper

• MEN2: surgical precision in the era of precision medicine

  2025cites this paper
• Diagnostic Performance of the 68Ga-Labeled Minigastrin Analog DOTA-MGS5 in Patients with Advanced Medullary Thyroid Cancer and Other Neuroendocrine Tumors

  2025cites this paper
• Medullary Thyroid Carcinoma: Imaging.

  2025cites this paper
• Patient-derived medullary thyroid cancer organoids: a potential model for mechanistic studies on diagnostics and therapy

  2025cites this paper
• PET/CT imaging of differentiated and medullary thyroid carcinoma using the novel SSTR-targeting peptide [18F]SiTATE – first clinical experiences

  2024cites this paper
• Comparison of Two Chelator Scaffolds as Basis for Cholecystokinin-2 Receptor Targeting Bimodal Imaging Probes

  2024cites this paper
• Pancreas as an Unusual Metastatic Site of Medullary Thyroid Carcinoma: A Case of Very Long-term Follow-up Under Prolonged Treatment with Somatostatin Analogues.

  2024cites this paper
• CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma

  2024cites this paper
• The role of [18F]F-DOPA PET/CT in diagnostic and prognostic assessment of medullary thyroid cancer: a 15-year experience with 109 patients

  2024cites this paper
• [18F]F-DOPA PET/CT May Be Useful in Diagnostic and Prognostic Evaluation of Recurrent MTC

  2024cites this paper
• Molecular imaging and related therapeutic options for medullary thyroid carcinoma: state of the art and future opportunities

  2023cites this paper
• Sensitivities evaluation of five radiopharmaceuticals in four common medullary thyroid carcinoma metastatic sites on PET/CT: a network meta-analysis and systematic review

  2023cites this paper
• Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [68Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer

  2023cites this paper
• SNMMI Procedure Standard/EANM Practice Guideline for SSTR PET: Imaging Neuroendocrine Tumors

  2023cites this paper
• Update on Management of Medullary Thyroid Carcinoma: Focus on Nuclear Medicine.

  2023cites this paper
• The Role of 18F-FDOPA PET/CT in Recurrent Medullary Thyroid Cancer Patients with Elevated Serum Calcitonin Levels

  2023influential citation
• A Contemporary Review of the Treatment of Medullary Thyroid Carcinoma in the Era of New Drug Therapies.

  2023cites this paper
• Current perspectives on the management of patients with advanced RET-driven thyroid cancer in Europe

  2023cites this paper
• Head-to-Head Comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC Positron Emission Tomography/Computed Tomography Imaging for the Follow-Up Surveillance of Patients with Medullary Thyroid Cancer

  2023cites this paper
• Targeting Amyloids with [18F]AV-45 for Medullary Thyroid Carcinoma Positron Emission Tomography/Computed Tomography Imaging: A Pilot Clinical Study

  2022cites this paper
• Medullary Thyroid Carcinoma presenting as an Incidentaloma on Gallium-68-PSMA-PET/

  2022cites this paper
• Role of PET/Computed Tomography in Elderly Thyroid Cancer: Tumor Biology and Clinical Management.

  2022cites this paper
• Feasibility and therapeutic potential of the 68Ga/177Lu-DOTATATE theranostic pair in patients with metastatic medullary thyroid carcinoma.

  2022cites this paper
• A Rare Case of Negative Serum Calcitonin in Metastatic Medullary Thyroid Carcinoma: Diagnosis, Treatment, and Follow-Up Strategy

  2022cites this paper
• Nuklearmedizinische Diagnostik des medullären Schilddrüsenkarzinoms

  2022cites this paper
• Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma

  2022cites this paper
• Prospective study on the clinical relevance of 18F-DOPA positron emission tomography/computed tomography in patients with medullary thyroid carcinoma

  2022cites this paper
• 68Ga-DOTATATE-PET shows promise for diagnosis of recurrent or persistent medullary thyroid cancer: A systematic review.

  2022cites this paper
• Functional imaging in thyroid cancer patients with metastases and therapeutic implications.

  2022cites this paper
• Correlation of somatostatin receptor PET/CT imaging features and immunohistochemistry in neuroendocrine tumors of the lung: a retrospective observational study

  2022cites this paper
• Medullary Thyroid Carcinoma

  2022cites this paper
• 18F-FDG PET/CT in Treatment Response Evaluation in Thyroid Cancer

  2021cites this paper
• Sporadisches medulläres Schilddrüsenkarzinom

  2021cites this paper
• PET/Computed Tomography in Thyroid Cancer.

  2021cites this paper
• Evaluation of F-18 DOPA PET/CT in the detection of recurrent or metastatic medullary thyroid carcinoma: comparison with GA-68 DOTA-TATE PET/CT

  2021cites this paper
• PET in medullary thyroid carcinoma

  2021cites this paper
• Updated Review of Nuclear Molecular Imaging of Thyroid Cancers.

  2021cites this paper
• Imaging medullary thyroid cancer patients with detectable serum markers: state of the art and future perspectives

  2021cites this paper
• Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy.

  2021cites this paper
• Diagnostic Challenges of Medullary Thyroid Carcinoma

  2021cites this paper
• Calcitonin-Negative Neuroendocrine Carcinoma of the Thyroid Gland: Case Report and Literature Review

  2021cites this paper
• Medullary thyroid carcinoma

  2021cites this paper
• Positronenemissionscomputertomografie (PET); Detektion pathologischer Lymphknoten mit Hilfe der Positronenemissionscomputertomografie

  2021cites this paper
• The Value of F18-FDG PET/CT in Medullary Thyroid Cancer Patients with Persistent Elevated Calcitonin Levels

  2020cites this paper
• Advances in the Diagnosis and Surgical Management of Medullary Thyroid Carcinomas

  2020cites this paper
• Multimodal imaging of thyroid cancer

  2020cites this paper
• Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma

  2020cites this paper
• The role of tumour biomarkers in choosing the appropriate positron emission tomography imaging in follow‐up of medullary thyroid cancer

  2020cites this paper
• Medullary Thyroid Carcinoma presenting as an Incidentaloma on Gallium-68-PSMA-PET/CT – Systematic Literature Review and Case Report

  2020cites this paper
• Cholecystokinin-2 receptor targeting with radiolabeled peptides: current status and future directions.

  2020cites this paper
• “Detecting the Undetectable”

  2020cites this paper
• Nuclear medicine and molecular imaging advances in the 21st century.

  2020cites this paper
• Which Is the Optimal Scan Time of 18F-DOPA PET/CT in Patients With Recurrent Medullary Thyroid Carcinoma?: Results From a Dynamic Acquisition Study.

  2020cites this paper
• Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma

  2020influential citation
• Usefulness of PET-CT scan in recurrent thyroid cancer

  2020cites this paper
• Non-FDG Radiopharmaceuticals in Head and Neck PET Imaging: Current Techniques and Future Directions.

  2019cites this paper
• Diagnostic Accuracy of 18F-FDG PET/CT in Patients With Biochemical Evidence of Recurrent, Residual, or Metastatic Medullary Thyroid Carcinoma

  2019cites this paper
• 68Ga-DOTANOC and 18F-FDG PET/CT in metastatic medullary thyroid carcinoma: novel correlations with tumoral biomarkers

  2019cites this paper
• Novel PET tracers: added value for endocrine disorders

  2019cites this paper
• Somatostatin Receptor Positron Emission Tomography: Beyond Gastroenteropancreatic Neuroendocrine Tumors

  2019cites this paper
• ACR Appropriateness Criteria® Thyroid Disease.

  2019cites this paper
• Medullary Thyroid Carcinoma: An Update on Imaging

  2019influential citation
• [Imaging of medullary thyroid carcinoma].

  2019cites this paper
• Nuclear Medicine Procedures in Neuroblastoma

  2019cites this paper
• PET/CT with [68Ga]DOTANOC Is More Sensitive Than [18F]FDG for Restaging of Metastatic Medullary Thyroid Cancer

  2019cites this paper
• F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients

  2019cites this paper
• Radioguided hepatic resection with 18F-DOPA in a patient with metastatic medullary thyroid carcinoma.

  2018cites this paper
• Neuroblastoma

  2018cites this paper
• Radioguided hepatic resection with l -DOPA in metastatic medullary thyroid carcinoma

  2018cites this paper
• [18F]DOPA PET/ceCT in diagnosis and staging of primary medullary thyroid carcinoma prior to surgery

  2018cites this paper
• Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives

  2018cites this paper
• Thyroid disease

  2018cites this paper
• Histology-proven recurrence in the lateral or central neck after systematic neck dissection for medullary thyroid cancer

  2018cites this paper
• Brain Metastasis of Medullary Thyroid Carcinoma Without Macroscopic Calcification Detected First on 68Ga-Dotatate and Then on 18F-Fluoride PET/CT.

  2018cites this paper
• Neuroendocrine Tumor Diagnosis and Management: 68Ga-DOTATATE PET/CT.

  2018cites this paper
• 18F-FDG and 68Ga-somatostatin analogs PET/CT in patients with Merkel cell carcinoma: a comparison study

  2018cites this paper
• Bone and Calcified Soft Tissue Metastases of Medullary Thyroid Carcinoma Better Characterized on 18F-Fluoride PET/CT than on 68Ga-Dotatate PET/CT

  2018cites this paper
• Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma

  2018cites this paper
• Comparison of 68Ga PET/CT to Other Imaging Studies in Medullary Thyroid Cancer: Superiority in Detecting Bone Metastases

  2018cites this paper
• Thyroid disease

  2018cites this paper
• Comparison between 11 C-acetate and 18 F-FDG Positron Emission Tomography ( PET ) in Thyroid Cancer-A retrospective Study Vergleich

  2018cites this paper
• Gastroenteropancreatic Neuroendocrine Neoplasms

  2018cites this paper
• PET imaging for thyroid cancers: Current status and future directions.

  2017cites this paper
• 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging

  2017influential citation
• SPECT/CT and PET/CT molecular imaging in medullary thyroid carcinoma. Are we running in the right direction?

  2017cites this paper
• Recent advances in the biology and therapy of medullary thyroid carcinoma

  2017cites this paper
• Detection rate of somatostatin receptor PET in patients with recurrent medullary thyroid carcinoma: a systematic review and a meta-analysis

  2017cites this paper
• 18F-FDOPA-PET Is More Sensitive than F-18-FDG-PET in Persistent or Recurrent Medullary Thyroid Cancer

  2017cites this paper
• A review of diagnostic approaches to medullary thyroid carcinoma

  2017cites this paper
• Radionuclide Imaging of Medullary Thyroid Carcinoma

  2017cites this paper
• The Accessory Spleen Is an Important Pitfall of 68Ga-DOTANOC PET/CT in the Workup for Pancreatic Neuroendocrine Neoplasm

  2017cites this paper
• Upregulated miR-9-3p Promotes Cell Growth and Inhibits Apoptosis in Medullary Thyroid Carcinoma by Targeting BLCAP

  2017cites this paper
• 18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth

  2017cites this paper
• Diagnostic utility of PET/CT with 18F-DOPA and 18F-FDG in persistent or recurrent medullary thyroid carcinoma: the importance of calcitonin and carcinoembryonic antigen cutoff

  2017cites this paper
• Novel acquisitions in the diagnosis of medullary thyroid carcinoma.

  2017cites this paper
• The value of 18F-DOPA PET/CT in patients with medullary thyroid carcinoma and increased calcitonin values

  2017cites this paper
• Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid

  2017cites this paper
• Charting a course through the CEAs: diagnosis and management of medullary thyroid cancer

  2016cites this paper
• Overexpression of L-Type Amino Acid Transporter 1 (LAT1) and 2 (LAT2): Novel Markers of Neuroendocrine Tumors

  2016cites this paper
• Evaluation of the Added Value of Diffusion-Weighted Imaging to Conventional Magnetic Resonance Imaging in Pancreatic Neuroendocrine Tumors and Comparison With 68Ga-DOTANOC Positron Emission Tomography/Computed Tomography

  2016cites this paper